Sanofi (SNY)
(Delayed Data from NSDQ)
$49.09 USD
-0.04 (-0.08%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $49.00 -0.09 (-0.18%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$49.09 USD
-0.04 (-0.08%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $49.00 -0.09 (-0.18%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth F Momentum B VGM
Zacks News
The Zacks Analyst Blog Highlights: UnitedHealth, 21st Century Fox, Sanofi, MasterCard and Barclays
by Zacks Equity Research
The Zacks Analyst Blog Highlights: UnitedHealth, 21st Century Fox, Sanofi, MasterCard and Barclays
Celgene vs. Regeneron: Which Stock is a Better Pick?
by Arpita Dutt
Both Celgene (CELG) and Regeneron (REGN) are Zacks Rank #2 (Buy) stocks; which one of these two stocks is a better choice for investors?
Pharma Industry Outlook: Pricing Pressure and M&As in Focus
by Arpita Dutt
According to a tracking poll, most Americans (72%) find drug costs unreasonable and 74% are of the view that drug companies put profits before people.
Pharma Industry Outlook: Pricing Pressure and M&As in Focus
by Arpita Dutt
According to a tracking poll, most Americans (72%) find drug costs unreasonable and 74% are of the view that drug companies put profits before people.
Pharma Stock Outlook - July 2015
by Arpita Dutt
Mergers, acquisitions and deals continue to take center-stage in the pharma sector. While 2014 turned out to be one of the most active years in the pharma sector where mergers and acquisitions and licensing agreements are concerned, the trend continues this year as well.
Pharma Stock Outlook - July 2015
by Arpita Dutt
Mergers, acquisitions and deals continue to take center-stage in the pharma sector. While 2014 turned out to be one of the most active years in the pharma sector where mergers and acquisitions and licensing agreements are concerned, the trend continues this year as well.